Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
How do you determine if generic vs brand formulation of a DMT is the probable cause of worsening multiple sclerosis disease activity?
In light of study on fingolimod brand vs generic by
Patel et al in Mult Scler 2026 Jan
Related Questions
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
When would you obtain optic nerve testing in patients suspected to have multiple sclerosis without a clinical history of optic neuritis?
What is your approach to treatment when there is a multiple sclerosis reactivation while on natalizumab?
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
How do you counsel patients interested in primary prevention of MS?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
What therapy do you recommend in situations where IV steroids and IVIg do not help patients with GABA-A encephalitis?
Is IVIG ever used to treat CNS neurosarcoidosis–related pain when the presentation is not consistent with peripheral neurosarcoid involvement?”
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?